Introduction

The pharmaceutical industry faces a critical trust challenge that threatens to undermine even its most groundbreaking innovations, according to Seth Ginsberg, co-founder and president of the Global Healthy Living Foundation (GHLF). Despite creating life-changing treatments, the industry struggles to connect authentically with the very patients it aims to serve.

"The only thing more powerful than a breakthrough drug is making sure patients actually trust and use it. Patients want medicine. They need medicine. But they're confused, they're skeptical, and they are drowning in noise."

- Ginsberg emphasized.

This disconnect occurs at a time when patients increasingly turn to social media and online communities for health information rather than traditional medical authorities. The result is a vacuum being filled by unvetted sources, from TikTok influencers to self-proclaimed health gurus, who often spread misinformation that can steer patients away from evidence-based treatments.

The Trust Deficit and Information Crisis

The current landscape presents a paradox: despite pharmaceutical companies investing billions in communication efforts, patient trust remains elusive. Ginsberg pointed to direct-to-consumer (DTC) television advertising as a prime example of this disconnect, suggesting these ads fail to resonate with today's patients.

"The moment these ads come on, patients are not thinking to themselves, 'Whoa, what an informative and trustworthy ad.' No, they're thinking, 'Where's the remote?'" Ginsberg observed. "We have never met a patient who said, 'I asked my doctor if a drug was right because I saw it on TV and I just had to have it.'"

This communication gap has real consequences. GHLF regularly receives messages from patients who lack basic understanding about their treatment options. Ginsberg shared an example: "We had a podcast recently where this rheumatoid arthritis patient reached out and literally wrote to us, 'No one ever told me that I could ask my doctor about switching medicines if my inflammation markers were still high.'"

Misinformation: The Real Competition

The pharmaceutical industry's greatest competitor isn't other companies but misinformation itself, which spreads rapidly through digital channels. This misinformation succeeds because it's typically simple, emotional, and engaging – qualities often missing from compliance-driven pharmaceutical communications.

"Misinformation spreads faster than facts because misinformation is simple, it's emotional, and it's engaging. And unlike your company's compliance department, misinformation moves quickly," Ginsberg noted. "Can we make evidence-based information just as simple, just as emotional, and just as engaging?"

The stakes are high, with GHLF observing entire patient communities turning away from legitimate treatments based on unfounded rumors. This reality presents both a challenge and an opportunity for pharmaceutical companies to rethink their approach to patient engagement.

A Path Forward: From Talking At to Talking With

Ginsberg outlined a framework for rebuilding patient trust through more authentic engagement:

1) Stop talking at patients and start talking with them - Create genuine two-way dialogue rather than one-way messaging

2) Be present where patients actually are - Engage in the digital spaces where health conversations naturally happen

3) Recognize that trust is today's new currency - Invest in building credibility through authentic communication

4) Partner with patient advocates who have earned trust - Leverage existing trusted voices within patient communities

This approach requires pharmaceutical companies to move beyond compliance-driven communication toward more patient-centered engagement. GHLF's own success with unbranded content demonstrates the potential impact – their podcast reaches over a million listeners organically, and their YouTube channel generates thousands of engaged conversations.

Bringing Compliance to the Table

A key element in transforming pharmaceutical communication is reimagining the role of legal and compliance teams. Rather than allowing them to function as "patient blocking committees," Ginsberg advocates for their early involvement in developing patient engagement strategies.

"Find a friend in compliance, get a lawyer on your side that understands the value and the impact of meaningful patient engagement and bring them to the party," he advised. "Encourage them to be a part of the development, give them access to patients who actually tell you what you need to hear."

This collaborative approach can help companies navigate regulatory requirements while still creating content that genuinely resonates with patients. As Ginsberg noted, "Truth and trust building aren't against FDA regulations yet."

Five Key Takeaways

1) Patients are seeking information, but often in the wrong places - "The reality is that most patients get health info from social media. Most patients don't trust pharma messaging. And a shocking number of patients would rather take advice from a random Internet stranger than from their doctor," Ginsberg explained.

2) Traditional DTC advertising is failing to build trust with today's patients and may face regulatory challenges under the new administration.

3) Misinformation succeeds because it's simple, emotional, and fast-moving - "The biggest competitor to science right now is not another pharma company. It's misinformation," warned Ginsberg.

4) Two-way communication is essential - "I think the overarching message would be exploring ways that one could listen as much as talk so that the engagement could be more authentic and the trust could be built organically."

5) Compliance teams should be partners, not obstacles - "Inclusion of the compliance team in allowing for a more trusted, engaging relationship with the patients is your literal only hope for success now in today's new media."

"Medical and commercial will always have their separate roles. They will always be distinct in what they need to do. But there is no reason why you cannot have a single objective or single set of objectives what you're trying to accomplish,"

she explains.

The solution isn't about breaking down regulatory boundaries but aligning on common goals: "If you can align on the goal, it's not about the activities, it's not about the details of the road, it's about, are you trying to move in the same direction?"

Fostering Innovation Through the 90/10 Rule

To drive meaningful innovation, Gopal advocates for the "90/10 rule"—dedicating 90% of resources to essential activities while reserving 10% for creative exploration. She cites Google's approach of allowing employees to spend 20% of their time on creative projects, which led to innovations like Gmail and Google News.

However, she cautions that once an innovation shows promise, it requires full commitment: "They cannot be side projects once you choose to do something with them. If you decide you're going to do something coming out of that 10%, you have to be all in."

Implementing Change

Gopal outlines three key principles for implementing change:

1. Establish clear objectives and stay committed: "Pick a lane, get alignment and stay committed. You cannot have a different plan every six months."

2. Involve the right stakeholders early: "Get the right people around the table to say, okay, this is the idea. How are we going to make this happen? Not do I have permission to make it happen."

3. Proceed with determination: "You have to be enthusiastic when you're trying to make change. You have to believe and you have to commit. And you can't back down."

"Agility in pharma is not a contradiction. It is absolutely possible," Gopal concludes. "We are nimble when we need to be. How are we going to be nimble when we want to be?"

Key Takeaways

1) Shift from reactive to proactive change: "Imagine if you could turn that around and make it about, I see a need, I see an opportunity, and I want to change something. That's what creates agility."

2) Align medical and commercial objectives: "If you can align on the goal, it's not about the activities, it's not about the details of the road, it's about, are you trying to move in the same direction?"

3) Implement the 90/10 rule for innovation: "Let's dedicate 90% of our budget to things that need to happen... But let's leave 10% to think about things that we normally wouldn't think about."

4) Prepare concrete action plans, not just scenarios: "Being competitive means preparing for the pivot and having a plan in place that we can use immediately."

5) Learn from cross-industry approaches: "We need to be curious. I learn a lot from other industries. I don't think any industry is better or worse at moving with speed than pharma is."

"That's one of my big missions in my team – that people are getting a flavor and a taste of all of the different components of this ecosystem between the data, the digital and the operations,"

she says. "The more we are thinking of that holistically across this whole area, the better off we're going to be anticipating and seeing around corners."

Key Takeaways

1) Start with the customer experience: "A big part of it is really starting with our customer as the first point. How do we think about that person's experience? The things that are making them frustrated or standing in their way."

2) Embrace difficult change management: "Standing true to the notion that ultimately, on the other side of those tough decisions, there's a better future for the organization and maybe even for those individuals who are impacted."

3) Adapt to the digital-native clinician: "Our clinicians are changing and that inherently means that the way we engage with those clinicians has to evolve with them."

4) Maximize each interaction: "The number of times we get in front of these clinicians nowadays is going to be a lot fewer per time period, so each one of those conversations needs to be that much better and that much more planned out."

5) Foster cross-functional thinking: "I want the entire team to be thinking about data, thinking about digital and thinking about operations, regardless of which place you are in your function."

Text

For more patient insights, including latest articles, interviews and more – click here